Toulouse, FRANCE, Lakeland, UNITED STATES, March 7, 2024, 7:00 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), new generation biotechnology company dedicated to the discovery and development of innovative therapies based solely on recombinant human apolipoprotein apoA-I in the world, today announces its forecast financial communication schedule for the year 2024.
2023 annual results: Monday March 11, 2024
Cash position and update on Q1 2024 activity: Thursday May 16, 2024
Cash position and update on Q2 2023 activity: Thursday August 22, 2024
2024 half-year results: Thursday September 26, 2024
Cash position and update on Q3 2024 activity: Thursday November 14, 2024
To receive information from ABIONYX Pharma in real time, send a request to [email protected].